Activity of Cabozantinib in Radioresistant Brain Metastases From Renal Cell Carcinoma

Two Case Reports

Sylvie Négrier; Guillaume Moriceau; Valéry Attignon; Véronique Haddad; Daniel Pissaloux; Nicole Guerin; Christian Carrie


J Med Case Reports. 2018;12(351) 

In This Article


These case reports indicate that orally administered cabozantinib is able to reach brain tumors and to induce regressions in metastases from RCC that were resistant to radiation and previous angiogenic TKI. A prospective trial with cabozantinib in patients with mRCC and brain metastases is required, as well as further investigations on the role of the MET gene in these patients.